P

Puma Biotechnology
D

PBYI

2.99500
USD
0.10
(3.28%)
Market Closed
Volume
18,798
EPS
0
Div Yield
-
P/E
6
Market Cap
147,017,614
OverviewSignalsIdeasNews
Related Instruments
    B
    BLUE
    -0.04270
    (-11.74%)
    0.32090 USD
    I
    INCY
    -1.840
    (-2.37%)
    75.890 USD
    N
    NKTR
    -0.11000
    (-9.36%)
    1.06500 USD
    S
    SGMO
    -0.10000
    (-4.67%)
    2.04000 USD
    X
    XLRN
    0
    (0%)
    0.000000 USD
    More
News

Title: Puma Biotechnology

Sector: Healthcare
Industry: Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.